Liew N C, Chang Y H, Choi G, Chu P H, Gao X, Gibbs H, Ho C O, Ibrahim H, Kim T K, Kritpracha B, Lee L H, Lee L, Lee W Y, Li Y J, Nicolaides A N, Oh D, Pratama D, Ramakrishnan N, Robless P A, Villarama-Alemany G, Wong R
Department of Surgery, University Putra Malaysia, General Hospital, Kuala Lumpur, Malaysia.
Int Angiol. 2012 Dec;31(6):501-16.
Venous thromboembolism (VTE) prophylaxis is under-utilized in Asia because of the misconception that its incidence is lower in Asians as compared to the Caucasians. The available data on VTE in Asia is limited due to the lack of well-designed multicenter randomized controlled trials as well as non-standardized research designs, making data comparison difficult. Emerging data indicates that the VTE incidence is not low in Asia, and is comparable to that reported in the Western literature in some instances. There is also a trend towards increasing incidence of VTE, as demonstrated by a number of hospital-based studies in Asia. This could be attributed to lifestyle changes, ageing population, increasing awareness of VTE and wider availability of Duplex ultrasound. The risk of VTE in hospitalized patients remain the same in Asians and Caucasians, even though there may be factors that are inherent to patients in Asia that influence the slight variation in incidence. The utilization rate of VTE prophylaxis remains suboptimal in Asia. The Asian Venous Thrombosis Forum (AVTF) comprises participants from various countries such as China, Hong Kong, India, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and experts from Australia and Europe. The forum evaluated the available data on VTE from the Asian region and formulated guidelines tailored to meet the needs of the region. We recommend that serious considerations are given to VTE prophylaxis especially in the at-risk group and a formal hospital policy be established to facilitate the implementation. On admission to the hospital, we recommend assessing the patients for both VTE and bleeding risk. We recommend mechanical prophylaxis for patients at increased risk of bleeding and utilizing it as an adjunctive measure in combination with pharmacological prophylaxis in patients with high risk of VTE. For patients undergoing general or gynecological surgery and with moderate risk for VTE, we recommend prophylaxis with one of the following: low dose unfractionated heparin (LDUH), low molecular weight heparin (LMWH), fondaparinux or intermittent pneumatic compression (IPC). For the same group of patients at high risk of VTE, we recommend pharmacological or combination of pharmacological and mechanical prophylaxis. For patients undergoing major orthopedic surgeries like total hip replacement, total knee replacement and proximal hip fracture surgery, we recommend using one of the following: LMWH, fondaparinux, rivaroxaban, apixaban, edoxaban, dabigatran, warfarin or aspirin with IPC. For patients admitted to the hospital with acute medical illness and has moderate risk of VTE, we recommend prophylaxis with LDUH, LMWH or Fondaparinux. For the same group at high risk of VTE, we recommend combination of pharmacological and mechanical prophylaxis.
由于存在亚洲人静脉血栓栓塞(VTE)发病率低于高加索人的误解,VTE预防措施在亚洲未得到充分利用。由于缺乏精心设计的多中心随机对照试验以及非标准化的研究设计,亚洲现有的VTE数据有限,这使得数据比较变得困难。新出现的数据表明,亚洲的VTE发病率并不低,在某些情况下与西方文献报道的发病率相当。亚洲一些基于医院的研究也表明,VTE发病率有上升趋势。这可能归因于生活方式的改变、人口老龄化、对VTE认识的提高以及双功超声检查的更广泛应用。尽管亚洲患者可能存在一些固有因素影响发病率的轻微差异,但亚洲和高加索住院患者的VTE风险仍然相同。亚洲VTE预防措施的利用率仍然不理想。亚洲静脉血栓形成论坛(AVTF)的参与者来自中国、中国香港、印度、印度尼西亚、韩国、马来西亚、菲律宾、新加坡、中国台湾、泰国等不同国家,以及澳大利亚和欧洲的专家。该论坛评估了亚洲地区VTE的现有数据,并制定了满足该地区需求的指南。我们建议认真考虑VTE预防措施,特别是在高危人群中,并制定正式的医院政策以促进实施。入院时,我们建议评估患者的VTE和出血风险。对于出血风险增加的患者,我们建议采用机械预防措施,并将其作为VTE高危患者药物预防的辅助措施。对于接受普通或妇科手术且VTE风险中等的患者,我们建议采用以下措施之一进行预防:低剂量普通肝素(LDUH)、低分子肝素(LMWH)、磺达肝癸钠或间歇充气加压(IPC)。对于同一组VTE高危患者,我们建议采用药物预防或药物与机械联合预防。对于接受全髋关节置换、全膝关节置换和近端髋部骨折手术等大型骨科手术的患者,我们建议采用以下措施之一:LMWH、磺达肝癸钠、利伐沙班、阿哌沙班、依度沙班、达比加群、华法林或阿司匹林联合IPC。对于因急性内科疾病入院且VTE风险中等的患者,我们建议采用LDUH、LMWH或磺达肝癸钠进行预防。对于同一组VTE高危患者,我们建议采用药物与机械联合预防。